Skip to content

NRX Pharmaceuticals, Inc. (NRXP) — insider trading

Health Care · NASDAQ

NRX Pharmaceuticals, Inc. (NRXP) has 7 reported SEC Form 4 insider transactions in our data, including 1 open-market purchase among the most recent 7 (latest 2026-01-27).

Recent Form 4 transactions

DateInsiderRoleTypeSharesPriceValueFiling
2026-01-27 Casper Joseph Michael Officer (Chief Operating Officer) Grant / award / vesting (derivative) 100,000 — $0 Form 4
2025-04-09 Flynn Patrick John Director Grant / award / vesting (derivative) 50,000 — $0 Form 4
2025-04-09 Hurvitz Chaim Director Grant / award / vesting (derivative) 25,000 — $0 Form 4
2025-04-09 McBride Dennis Director Grant / award / vesting (derivative) 25,000 — $0 Form 4
2025-04-09 Javitt Jonathan C Director, Officer (Chairman and Chief Scientist), 10% owner Grant / award / vesting (derivative) 125,000 — $0 Form 4
2025-02-07 ABRAMS MICHAEL S Officer (Chief Financial Officer) Grant / award / vesting (derivative) 50,000 — $0 Form 4
2024-12-17 Javitt Jonathan C Director, Officer (Chairman and Chief Scientist), 10% owner Open-market purchase 40,000 $1.17 $46.8K Form 4

Ask the chat about NRXP's insider activity →

Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.

Source: SEC EDGAR Form 3/4/5. See the full company profile: NRX Pharmaceuticals, Inc. (NRXP).

Last updated 2026-01-27 (most recent filing date).

Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.